FY25 consensus (40c). The company continues to expect net sales to be in the range of $282M-$288M, representing growth of between 4.2%-6.4% over fiscal 2024 pro forma revenue of $270.7M, consensus $283.86M.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANGO:
- Options Volatility and Implied Earnings Moves This Week, January 06 – January 10, 2025
- Is ANGO a Buy, Before Earnings?
- Omnicom to acquire Interpublic, China to investigate Nvidia: Morning Buzz
- AngioDynamics receives FDA 510(k) clearance for NanoKnife System
- AngioDynamics Shareholder Approvals and Director Elections